Analysts' ratings for Boston Scientific BSX over the last quarter vary from bullish to bearish, as provided by 19 analysts.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 10 | 8 | 1 | 0 | 0 |
| Last 30D | 0 | 0 | 0 | 0 | 0 |
| 1M Ago | 5 | 5 | 0 | 0 | 0 |
| 2M Ago | 3 | 2 | 1 | 0 | 0 |
| 3M Ago | 2 | 1 | 0 | 0 | 0 |
Analysts have recently evaluated Boston Scientific and provided 12-month price targets. The average target is $96.63, accompanied by a high estimate of $110.00 and a low estimate of $86.00. This current average reflects an increase of 8.57% from the previous average price target of $89.00.
Diving into Analyst Ratings: An In-Depth Exploration
A clear picture of Boston Scientific's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Lee Hambright | Bernstein | Raises | Outperform | $100.00 | $92.00 |
| Patrick Wood | Morgan Stanley | Raises | Overweight | $100.00 | $92.00 |
| Shagun Singh | RBC Capital | Raises | Outperform | $98.00 | $95.00 |
| Larry Biegelsen | Wells Fargo | Raises | Overweight | $98.00 | $87.00 |
| Joanne Wuensch | Citigroup | Raises | Buy | $98.00 | $92.00 |
| William Plovanic | Canaccord Genuity | Maintains | Buy | $98.00 | $98.00 |
| Anthony Petrone | Mizuho | Raises | Outperform | $110.00 | $100.00 |
| Bob Hopkins | B of A Securities | Raises | Buy | $100.00 | $90.00 |
| Joshua Jennings | TD Cowen | Raises | Buy | $100.00 | $86.00 |
| William Plovanic | Canaccord Genuity | Raises | Buy | $98.00 | $88.00 |
| Rick Wise | Stifel | Raises | Buy | $100.00 | $85.00 |
| Mike Matson | Needham | Maintains | Hold | $86.00 | $86.00 |
| Marie Thibault | BTIG | Raises | Buy | $93.00 | $84.00 |
| Richard Newitter | Truist Securities | Raises | Buy | $100.00 | $90.00 |
| Shagun Singh | RBC Capital | Raises | Outperform | $95.00 | $85.00 |
| Vijay Kumar | Evercore ISI Group | Raises | Outperform | $90.00 | $82.00 |
| Jayson Bedford | Raymond James | Raises | Strong Buy | $94.00 | $91.00 |
| Joanne Wuensch | Citigroup | Raises | Buy | $92.00 | $90.00 |
| Matt Miksic | Barclays | Raises | Overweight | $86.00 | $78.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Boston Scientific. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Boston Scientific compared to the broader market.
- Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Boston Scientific's stock. This comparison reveals trends in analysts' expectations over time.
For valuable insights into Boston Scientific's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on Boston Scientific analyst ratings.
Unveiling the Story Behind Boston Scientific
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Unraveling the Financial Story of Boston Scientific
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Boston Scientific's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 19.34%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Boston Scientific's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 11.14%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Boston Scientific's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 2.28%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Boston Scientific's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 1.25%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Boston Scientific's debt-to-equity ratio is below the industry average at 0.54, reflecting a lower dependency on debt financing and a more conservative financial approach.
The Core of Analyst Ratings: What Every Investor Should Know
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
